Trial Profile
The Shuttle Effect : Combination Therapy With Deferiprone and Deferasirox in Transfusion-dependent Thalassemia Patients.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Deferasirox (Primary) ; Deferiprone (Primary)
- Indications Thalassaemia
- Focus Pharmacokinetics
- 30 Jul 2014 New trial record